Neurocrine kept at sell by Merrill

Merrill Lynch analyst Eric Ende maintained Neurocrine Bioscience Inc. at its downgraded sell rating following the Food and Drug Administration's request for additional Indiplon studies and the resulting stock sell off. It is possible that Pfizer may give Indiplon back to Neurocrine, reducing the drug's market opportunity. Shares of the San Diego-based pharmaceutical company were down $1.06, or 6.98%, at $14.12 on volume of 7,023,714 shares versus the three-month running average of 2,354,450 shares. (Nasdaq: NBIX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.